Multiple SclerosisMethotrexateMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveSclerosisAmyotrophic Lateral SclerosisEncephalomyelitis, Autoimmune, ExperimentalTuberous SclerosisDemyelinating DiseasesPolyglutamic AcidOptic NeuritisMagnetic Resonance ImagingMyelin Basic ProteinAntirheumatic AgentsScleroderma, SystemicBrainOligoclonal BandsInterferon-betaMyelin SheathFolic Acid AntagonistsMyelin-Oligodendrocyte GlycoproteinSpinal CordTetrahydrofolate DehydrogenaseDisability EvaluationArthritis, RheumatoidMyelin ProteinsOligodendrogliaMyelin-Associated GlycoproteinDisease ProgressionImmunosuppressive AgentsNeuromyelitis OpticaAminopterinCentral Nervous SystemAntimetabolites, AntineoplasticImmunologic FactorsTreatment OutcomeMyelin Proteolipid ProteinLeukemia L1210Reduced Folate Carrier ProteinAtrophySeverity of Illness IndexTrimetrexateDrug Therapy, CombinationRecurrenceHLA-DR2 AntigenEncephalomyelitis, Acute DisseminatedFolic AcidCase-Control StudiesRemission, SpontaneousTime FactorsDisease Models, AnimalCuprizoneCyclophosphamideNerve Fibers, MyelinatedDiffuse Cerebral Sclerosis of Schildergamma-Glutamyl HydrolasePropylene GlycolsLeucovorinDemyelinating Autoimmune Diseases, CNSTetrahydrofolatesCerebrospinal FluidTheilovirusAxonsCerebrospinal Fluid ProteinsAbortifacient Agents, NonsteroidalImmunoglobulin GNervous System DiseasesFollow-Up StudiesDrug ResistanceT-LymphocytesDrug Administration ScheduleAge of OnsetMethylprednisoloneAntineoplastic Combined Chemotherapy ProtocolsHLA-DRB1 ChainsMice, Inbred C57BLMicrogliaBlood-Brain BarrierDose-Response Relationship, DrugAutoimmune DiseasesVincristineSulfasalazineOptic NerveFatigueDeoxyuridinePrecursor Cell Lymphoblastic Leukemia-LymphomaScleroderma, DiffuseCells, CulturedDermatologic AgentsInjections, SpinalCardiovirus InfectionsCentral Nervous System DiseasesNeurologic Examination6-MercaptopurineAutoimmunityAutoantibodiesProspective StudiesPregnancy, EctopicAntibodies, MonoclonalRetrospective Studies